• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Pemetrexed
    2 Drugs classified under this active ingredient


    All the Active Ingredient Drugs

    Alimta
    Eli Lilly
    RX
    partial basket chart
    Alimta

    Antimetabolite (antifolate). Pemetrexed 100 mg, 500 mg.
    VIAL: 1X 100 mg, 500 mg. Comb. use
    with cisplatin: 500 mg/m2 I.V. over 10
    mins. on day 1 of each 21-day cycle.
    Recommend. dose cisplatin: 75 mg/m2
    I.V. over 2 hrs. begin. 30 mins. aft. end
    of Alimta admin.
    Monother: 500 mg/m2 IV over 10 mins.
    on the 1 day of each 21-day cycle. See
    lit.
    In comb. with cisplatin for tmt.: malignant
    pleural mesothelioma whose dis.
    unresectable or otherwise not candidates
    for curative surg.; first line tmt. locally
    advanced/ metastat. non-small cell
    lungcancer other than predom. Squamous
    cell histology. As monother: in local.
    advanced/ metastat. non-small cell lung
    cancer other than predom. squamous cell
    histology histology in patients whose dis.
    has not progressed immediately following
    platinum-based chemotherapy; second
    line tmt. locally advanced/metastat.
    nonsmall cell lung cancer, other than
    predom. squamous cell histology.
    C/I: Hypersens., lact., concom. yellow
    fever vaccine.

    Pemetrexed Teva
    Abic
    RX
    partial basket chart
    Pemetrexed Teva

    Folic Acid Analog. Pemetrexed 100, 500, 1000 mg.
    VIAL (Pwdr. for conc. for sol. for infus.): 1 x 100 mg, 500 mg, 1000 mg. Tmt. to be initiated by physician experienced in the use of anticancer ther. In comb. with cisplatin: recomm. dose is 500 mg/m2 of BSA admin. as IV infus. over 10 min. on the 1st day of each 21 d cycle. The recomm. dose of cisplatin is 75 mg/m2 BSA infus. over 2 h approx. 30 min. after completion of pemetrexed infus. on the 1st  d of each 21 d cycle. As single agent: In pts. treated for NSCLC after prior chemother., the recomm. dose is 500 mg/m2 BSA admin. as IV infus. over 10 min. on the 1st d of each 21d cycle. See lit.
    Malignant pleural mesothelioma: in comb. with cisplatin is indic. for the tmt. of pts. with malign. pleural mesothelioma whose dis. is unresectable or who are otherwise not candidates for curatible surgery. Non-small cell lung cancer: In comb. with cisplatin is indic. for the 1st  line tmt. of pts. with locally adv. or metast. non-small cell lung cancer other than predominantly squamous cell histology. As monother. for the mainten. tmt. of locally adv. or metast. non-small cell lung cancer other than predominantly squamous cell histology in pts. whose dis. has not progressed immed. follow. platinum-based chemotherapy.  As monother. for the 2d  line tmt. of pts. with locally adv. or metast. non-small cell lung cancer other than predominantly squamous cell histology.
    C/I: Hypersens., Lact., Concom. yellow fever vacc.

    CLOSE